IMMX · Immix Biopharma, Inc. · Executive Compensation
$8.05
-0.01 (-0.12%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which may materially and adversely affect its business, financial condition and operations.”View the 10-Q filed Aug 7, 2026
Market Cap
$576.61M
Shares
71.54M
Volume · Oct 27
1.15M
Avg daily vol (3M)
1.54M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Gabriel Morris | Chief Financial Officer | $1,352,854 |
| Ilya Rachman | Chief Executive Officer | $1,352,854 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Gabriel Morris | Chief Financial Officer | $1,267,158 |
| Ilya Rachman | Chief Executive Officer | $1,267,158 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Gabriel Morris | Chief Financial Officer | $1,129,881 |
| Ilya Rachman | Chief Executive Officer | $1,129,881 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ilya Rachman | Chief Executive Officer | $2,356,145 |
| Gabriel Morris | Chief Financial Officer | $2,356,145 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Gabriel Morris | Chief Financial Officer | $462,091 |
| Ilya Rachman | Chief Executive Officer | $396,731 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Ilya Rachman | Chief Executive Officer | — |
| Gabriel Morris | Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Nancy Chang, Ph.D. | member of the Board | Appointed | 2025-09-08 |
| Yekaterina Chudnovsky | director | Appointed | 2024-06-14 |
| Helen C. Adams | director | Appointed | 2024-06-14 |
| Jane Buchan | director | Appointed | 2024-06-14 |
| Carey Ng | director | Appointed | 2024-06-14 |
| Jason Hsu | director | Appointed | 2024-06-14 |
| Magda Marquet | director | Appointed | 2024-06-14 |
| Gabriel Morris | director | Appointed | 2024-06-14 |
| Ilya Rachman | director | Appointed | 2024-06-14 |
| Yekaterina Chudnovsky | Board of Directors | Appointed | 2023-08-22 |
| Yekaterina Chudnovsky | member of the Board | Appointed | 2023-08-22 |
Leadership
- Ilya Rachman CEO, Board Member
- Gabriel Morris CFO, Board Member
- Carey Ng Board Member
- Helen C. Adams Board Member
- Jane Buchan Board Member
- Jason Hsu Board Member
- Magda Marquet Board Member
- Nancy Chang Board Member
- Nancy Chang, Ph.D. Board Member
- Yekaterina Chudnovsky Board Member
Key facts
CIK
1873835
CUSIP
45258H106
13F (30d)
12 filings
12 filers
Visit website
Investor relations